Immune Checkpoint Therapeutics Industry - Hot Targets & Pipeline Analysis Research Report

Wednesday, April 27, 2016 Research News J E 4
Advertisement add report on "Immune Checkpoint Therapeutics - Hot Targets & Pipeline Analysis" covers all the drugs being developed in various phases

PUNE, India, April 26, 2016 /PRNewswire-iReach/ -- The report "Immune Checkpoint Therapeutics – Hot Targets & Pipeline Analysis" gives comprehensive insights on the various Immune Checkpoint modulators being developed for the treatment of various diseases. The report covers all the drugs being developed in various phases (Discovery, Preclinical & Clinical development). The pipeline focuses on novel medicines covering small molecules, monoclonal antibodies, Recombinant proteins, Bi-specific Ab's, Antibody drug conjugates, Cell therapy, Peptides, Oncolytic viruses and Vaccines. The report also covers hot targets in research for Checkpoint modulators.

Photo -

Access a Report Copy @

This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Immune Checkpoints Drug market. The report also provides strategic insights on medicines that are likely to have an impact on future Immune Checkpoint treatment space. The report in addition to the monotherapy covers the pipeline for combination therapies associated only with checkpoint agents.

In order to effectively deal various diseases, the immune system needs to be able to generate an appropriate counter response. However, as a part of the natural fail–safe mechanism, to limit overactive immune responses that could lead to an auto-immune disease, there are a number of markers ("immune checkpoint receptors") found on both tumor cells and antigen presenting cells (dendritic cells, macrophages etc.) that can down-regulate or suppress T cells once the corresponding ligand is bound. Currently, Researchers are challenged to identify various avenues to prevent T cells from binding these tolerance-inducing ligands either through antibodies or recombinant forms of ligand or receptors. So, these T cells remain active and ready to tackle various diseases. Owing to its high response rate and prolonged overall patient survival the checkpoint therapeutics are gaining in popularity and have shown some impressive results in the areas of Oncology, Inflammation, Respiratory, Autoimmune and Infectious disease.

Purchase a 1-User License Copy @

Major Points in Table of Content

REPORT DESCRIPTION INTRODUCTION• Emerging role of immunotherapy • Immune checkpoints

HOT TARGETS• Immune checkpoints-Types • Stimulatory checkpoint pathways • Inhibitory checkpoint pathways • Targets – Immune checkpoints • Other immune checkpoint targets • Top companies based on revenue • Top companies based on Pipeline

MARKET SIZING & DEALS ANALYSIS• Market dynamics• Market sizing• Immune checkpoint Deals

PIPELINE ANALYSIS• Development stage• Leading players• Target analysis• Modalities• Therapeutic Segmentation•Oncology immune checkpoint pipeline by indication

SMALL MOLECULES• Pipeline• Competitive landscape MONOCLONAL ANTIBODIES• Pipeline• Competitive landscape RECOMBINANT FUSION PROTEINS• Pipeline• Competitive landscape BISPECIFIC ANTIBODIES• Pipeline• Competitive landscape ANTIBODY DRUG CONJUGATES (ADC's)• Pipeline• Competitive landscape

OTHERS• Pipeline• Competitive landscape

MAJOR PLAYERS • Company Profiles • Overview, Pipeline & Deals

Request a sample copy @

Contact for More Information at or +1 (646) 845 9349 (US) and +44 208 133 9349 (UK)

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.

Media Contact: Norah Trent, WiseGuy Reports, +1 646 845 9349,

News distributed by PR Newswire iReach:

SOURCE WiseGuy Reports



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Global Peripheral Artery Disease Market 2016 Trend...
Minimally Invasive HIFU Available in Beverly Hills...